clinical trial · NCT06997627
A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults
Tetanus-diphtheria-acellular Pertussis (Tdap)GC3111BBoostrix®
brief summary
This clinical trial consists of two parts: Part 1, which explores safety, and Part 2, which examines both safety and efficacy (immunogenicity). Part 1 is a single-center, open-label, single-group study, while Part 2 is designed as a multicenter, double-blind, randomized, active-controlled trial.
started
Jun 5, 2025
primary completion
May 1, 2026
completion
May 1, 2026
last updated
Jul 10, 2025
official title
An Open(Part 1), Single-arm(Part 1), Randomized(Part 2), Double-blind(Part 2), Active-controlled(Part 2) Phase I/II Clinical Trial to Evaluate the Safety and Efficacy (Immunogenicity) of GC3111B in Healthy Adults
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol